Search
Search Results
-
CYSTATIN C AS AN EARLY MARKER OF RENAL DYSFUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGES 1–2
Chronic kidney disease (CKD) is a prevalent condition characterized by an asymptomatic early course and a high risk of cardiovascular complications. Early detection remains challenging, as traditional markers such as serum creatinine have limited sensitivity in the initial stages.
This study aimed to evaluate the clinical and laboratory characteristics of patients with CKD stages 1–2 and to assess the diagnostic value of cystatin C as an early biomarker of renal dysfunction. A total of 88 patients were divided into stage 1 (n = 53) and stage 2 (n = 35) groups. Comprehensive clinical and laboratory assessments were performed.
Patients with CKD stage 2 were older and had a longer disease duration. While creatinine levels were moderately elevated, the most significant differences were observed in cystatin C levels (p < 0.001). ROC analysis demonstrated high diagnostic accuracy of cystatin C (AUC = 0.89), with a cut-off value of ≥18.0 mg/L providing 84.6% sensitivity and 81.1% specificity.
Cystatin C is a sensitive and specific marker for early renal dysfunction and may improve early diagnosis and management of CKD. -
IMPACT OF COMORBID CONDITIONS ON THE DEVELOPMENT OF NEPHROTOXICITY IN PATIENTS RECEIVING ANTI-TUBERCULOSIS THERAPY
Objective: To assess the influence of comorbid conditions—including anemia, diabetes mellitus, chronic kidney disease, hepatitis, and HIV/AIDS—on the dynamics of nephrotoxicity markers in patients undergoing anti-tuberculosis therapy.
Methods: A prospective–retrospective analysis was conducted to evaluate changes in glomerular filtration rate (GFR, CKD-EPI) and urinary cystatin C levels over a 210–240-day treatment period. Patient groups were compared according to the presence or absence of comorbidities.
Results: Anemia, diabetes mellitus, and hepatitis contributed significantly to fluctuations in GFR and urinary cystatin C, whereas HIV/AIDS had a limited impact. The most pronounced differences between groups were observed at specific time points (days 30, 60, and 120).
Conclusion: Comorbid conditions can potentiate the nephrotoxic effects of anti-tuberculosis medications, underscoring the need for differentiated and individualized renal monitoring. -
PREVENTION OF THE DEVELOPMENT AND PROGRESSION OF CKD IN PATIENTS WITH COVID-19
The article is devoted to the study of diagnostic, preventive, and rehabilitation features of nephropathies in patients who have recovered from COVID-19. The study included 249 patients who underwent inpatient treatment for COVID-19 at the Bukhara Regional Multidisciplinary Medical Center. Renal function parameters (creatinine, urea, cystatin C, microalbuminuria) were analyzed dynamically at 6, 12, 18, and 24 months after infection. It was found that 55.4% of patients developed albuminuria, which was most pronounced in individuals with comorbidities such as arterial hypertension, type 2 diabetes mellitus, and obesity. Key risk factors for post-COVID nephropathy were identified, and an individualized prevention system was proposed, including laboratory screening, a nephroprotective diet, physical activity, and staged monitoring. The findings confirm the importance of early diagnosis and rehabilitation to prevent the progression of chronic kidney disease after COVID-19.